Biocryst Pharmaceuticals (BCRX) Share-based Compensation (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Share-based Compensation came in at $16.0 million in Q1 2026, up 1086.31% YoY from $1.4 million in Q1 2025, and down 32.64% on a QoQ basis from $23.8 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Share-based Compensation (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Share-based Compensation data on file, last reported at $16.0 million in Q1 2026.
- Quarterly Share-based Compensation rose 1086.31% year-over-year to $16.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $99.7 million (up 1426.04% YoY) and the FY2025 annual result came in at $85.1 million, up 1028.94% from the prior year.
- Share-based Compensation retreated to $16.0 million in Q1 2026, from $23.8 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $59.1 million in Q3 2025 to a low of -$29.4 million in Q4 2022.
- A 5-year average of $11.7 million and a median of $9.7 million in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2025 — Share-based Compensation sank 96.46% — and 2026, when it soared 1086.31%.
- Tracing BCRX's Share-based Compensation over 5 years: stood at -$29.4 million in 2022, then surged by 289.04% to $55.6 million in 2023, then slumped by 94.45% to $3.1 million in 2024, then jumped by 671.5% to $23.8 million in 2025, then slumped by 32.64% to $16.0 million in 2026.
- The last three Share-based Compensation figures came in at $16.0 million (Q1 2026), $23.8 million (Q4 2025), and $59.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.45 Bn | 2.10 Bn | 214.41 Mn | 14.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.69 Mn |
| Jun 30, 2026 | 14.69 Mn |
| Mar 31, 2026 | 16.03 Mn |
| Mar 31, 2026 | 16.03 Mn |
| Dec 31, 2025 | 23.79 Mn |
| Dec 31, 2025 | 23.79 Mn |
| Sep 30, 2025 | 59.06 Mn |
| Sep 30, 2025 | 59.06 Mn |
| Jun 30, 2025 | 866,000.00 |
| Jun 30, 2025 | 866,000.00 |
| Mar 31, 2025 | 1.35 Mn |
| Mar 31, 2025 | 1.35 Mn |
| Dec 31, 2024 | 3.08 Mn |
| Dec 31, 2024 | 3.08 Mn |
| Sep 30, 2024 | -22.37 Mn |
| Sep 30, 2024 | -22.37 Mn |
| Jun 30, 2024 | 24.48 Mn |
| Jun 30, 2024 | 24.48 Mn |
| Mar 31, 2024 | 2.35 Mn |
| Mar 31, 2024 | 2.35 Mn |